Skip to main content

Children’s Tumor Foundation at the BIO International Convention

By June 3, 2019December 18th, 2023Science & Research

Annette Bakker to Speak on Innovative Research Collaborations and the Delivery of Safe and Effective Medicines for Patients

Global biotech and pharma leaders are convening this week in Philadelphia for the BIO International Convention, which focuses on the discovery of next generation products, therapies and cures for patients.  The Children’s Tumor Foundation (CTF) will be there, and its President, Annette Bakker, PhD, has been invited to participate on two important panels: one dedicated to innovative collaborations that speed up research, and the other on delivering safe and effective medicines to patients. She will share insights on CTF’s strategies, successes, and future priorities in the Foundation’s work to end neurofibromatosis (NF).

Information about CTF’s participation at BIO are as follows:

Innovative Collaborations to Speed Science to Patients” – June 5, 2019 at 11:00 AM


  • Freda C. Lewis-Hall, Executive Vice President and Chief Medical officer, Pfizer


  • Annette Bakker, President, Children’s Tumor Foundation
  • Tanisha Carino, Executive Director, FasterCures, Milken institute
  • Melanie Lee, Chief Executive officer, LifeArc
  • Jeffrey Schwartz, Managing Director, Bain Capital Life Sciences

This session will address the barriers to developing medicines for specific patient populations and how to get innovation to where it’s needed, including different mechanisms to bring products to market and improve access. More on this session can be found here.

“Building a Brighter Future for Children: How will large pediatric trial networks help to deliver safe, effective medicines?” June 5, 2019 at 4:15 PM


  • Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI)


  • Gerri Baer, Chief Medical Officer, Neonatology Team leader, Office of Pediatric Therapeutics, U.S. Food and Drug Administration
  • Annette Bakker, President, Children’s Tumor Foundation
  • Sam Maldonado, Vice President, Head of Child Health Innovation and Leadership Development (CHILD), Johnson & Johnson

This Innovative Medicines Initiative (IMI) session will discuss initiatives in both the United States and Europe focused on improving and facilitating the participation of children in novel trial designs. The Children’s Tumor Foundation is an associated partner of the IMI. More on this session can be found here.